top of page


Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
03/09/2026 FDA granted Fast Track Designation to YUTREPIA® for the treatment of Raynaud's phenomenon associated with systemic sclerosis. FDA granted Fast Track Designation to YUTREPIA® for the treatment of Raynaud's phenomenon associated with systemic sclerosis. (Ref) Liquidia Corporation announced that the US FDA had granted Fast Track designation to YUTREPIA® (treprostinil) inhalation powder for the treatment of Raynaud's phenomenon associated with systemic sclerosis (SSc-R
decodeMR Team
Sep 41 min read
bottom of page